传感器类型
电化学生物传感器
检测对象
癌胚抗原(carcinoembryonic antigen, CEA);样品基质:人尿液(1/20稀释加标)及Tris-HCl缓冲液标准品
检测原理
该传感器以CNP-PEI/SPGE为电化学界面,表面通过戊二醛共价固定抗CEA抗体(rCEA)。样品中的CEA与固定抗体特异性结合后,再加入rCEA-CdS QD,形成“固定抗体—CEA—标记抗体”三明治免疫复合物。CdS QD作为生物示踪剂,其结合量与CEA浓度成正比。随后加入HNO3溶解结合态CdS QD,释放Cd2+;在含Hg2+的醋酸缓冲液中,Cd2+经预处理和电沉积形成汞齐,再用SWASV阳极溶出,产生与Cd2+量成正比的峰电流。CNP-PEI膜提高电极电子转移和表面积,CdS QD提供信号放大,从而实现低浓度CEA的电化学检测。
检测灵敏度
LOD: 32 pg/mL(相当于5 µL样品中160 fg);线性范围: 0.032–10 ng/mL
效应效果
该传感器对CEA检测重现性良好,不同浓度重复分析平均CV不超过10%;同一人尿样1 h内连续5次测定峰电流CV为17%。人尿加标回收率为108.8%(1/20稀释尿,加入1.000 ng/mL,测得1.088 ng/mL)。与文献方法相比,LOD 0.032 ng/mL、线性范围0.032–10 ng/mL,优于压电免疫传感器(1500 ng/mL)、阻抗免疫传感器(28.0 ng/mL)、金纳米颗粒/壳聚糖电化学免疫传感器(1.0 ng/mL)和酚硼酸自组装层(1.1 ng/mL),与硫堇掺杂磁性金纳米球体系(0.005 ng/mL)相当。作者认为一次性SPGE平台可用于尿CEA检测,有助于尿路上皮癌早期筛查及POCT/家庭自诊。
传感器的构成
- 基底/换能器电极:丝网印刷石墨电极(SPGE),含石墨工作电极、碳对电极和Ag/AgCl参比电极,提供电化学检测界面。
- 纳米材料修饰层:碳纳米颗粒(CNP)与聚乙烯亚胺(PEI)复合膜,涂覆于SPGE工作电极,增强电子转移、增大比表面积并固定抗体。
- 交联/识别固定层:戊二醛(glutaraldehyde)作为双功能交联剂,将抗CEA抗体(rCEA)共价固定于CNP-PEI/SPGE表面。
- 识别元件:多克隆抗CEA抗体(rCEA),特异性捕获样品中的CEA。
- 信号标记物:巯基十一烷酸(MUA)封端的硫化镉量子点(CdS QDs),经EDC/sulfo-NHS偶联抗CEA抗体形成rCEA-CdS QD生物示踪剂,与CEA形成三明治免疫复合物。
- 信号释放/沉积介质:0.1 M HNO3溶解结合态CdS QD释放Cd2+;0.1 M醋酸缓冲液(pH 4.6)含65 ppm Hg(NO3)2,促进Cd2+汞齐化/沉积与剥离。
- 读出方式:方波阳极溶出伏安法(SWASV),通过Cd2+溶出峰电流定量CEA。
中文摘要
本研究开发了一种高灵敏度电化学免疫分析系统,用于检测蛋白肿瘤标志物癌胚抗原(CEA)。该系统以碳纳米颗粒(CNP)/聚乙烯亚胺(PEI)修饰的丝网印刷石墨电极(CNP-PEI/SPGE)为基底,并在其表面固定抗CEA抗体(rCEA)。检测采用三明治免疫复合物策略:先由CNP-PEI/SPGE上的rCEA捕获样品中的CEA,再加入经rCEA敏化的硫化镉纳米晶量子点(rCEA-CdS QD)作为生物示踪剂。随后用方波阳极溶出伏安法(SWASV)检测溶解后的rCEA-CdS QD所产生的电流响应。CNP增强电子转移,CdS纳米晶提供信号放大,从而提高CEA的灵敏度和检出限。校准曲线在0.032–10 ng/mL范围内线性,检出限为32 pg/mL(相当于5 µL样品中160 fg)。该方法精密度和灵敏度良好,可用于尿CEA检测,而尿CEA是比血清CEA更适合早期检测尿路上皮癌的指标。
英文摘要
We have developed a sensitive electrochemical immunoassay system for the detection of a protein tumor marker, carcinoembryonic antigen (CEA), that is based on a carbon nanoparticle (CNP)/poly(ethylene imine) (PEI)-modified screen-printed graphite electrode (CNP-PEI/SPGE) covered with anti-CEA antibodies. The signal amplification strategy--using CdS nanocrystals as biotracers and CNPs to enhance electron transfer--improves the sensitivity and detection limit for CEA, suggesting that this system holds promise for development into a point-of-care or disposable home-care self-diagnostic tool. This biosensor is based on a sandwich complex immunoassay, which we assembled from sequential layers of the anti-CEA antibody (alphaCEA) on CNP-PEI/SPGE, the CEA sample, and the CdS nanocrystal quantum dots (QDs) sensitized with alphaCEA (alphaCEA-CdS QD). We used square wave anodic stripping voltammetry (SWASV) to amplify the signal current response obtained from the dissolved alphaCEA-CdS QDs. The calibration curve for CEA concentration was linear in the range of 0.032-10 ng/mL; the detection limit (estimated as the mean of the blank sample plus three times the standard deviation obtained on the blank sample) was 32 pg/mL (equivalent to 160 fg in a 5 microL sample). This method is suitably precise and sensitive to function as a means of determining urinary CEA, which is a better marker than serum CEA for the early detection of urothelial carcinoma.